Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04022343 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer
A Phase 2 study of Renal Cell Carcinoma and Clear Cell Renal Cell Carcinoma, sponsored by Emory University.
- Active
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT04022343: Active Phase 2 study of Renal Cell Carcinoma and Clear Cell Renal Cell Carcinoma, sponsored by Emory University.
NCT04022343 is a Phase 2 study of Renal Cell Carcinoma and Clear Cell Renal Cell Carcinoma that is active but no longer recruiting, run by Emory University. The registered enrollment target is 22 participants, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04022343, a Phase 2 study of Renal Cell Carcinoma and Clear Cell Renal Cell Carcinoma, is active but no longer recruiting, sponsored by Emory University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II clinical trial studies how well cabozantinib works in treating patients with kidney cancer before surgery. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Primary Outcome
Objective response rate will be evaluated using Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) criteria. All tumor measurements must be recorded in centimeters. For target lesions, a complete response (CR) is defined as the disappearance of all target lesions. A partial response (PR) is defined as at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter.
Conditions Studied
Interventions
- DRUG Cabozantinib
Study Locations (1)
Georgia
- Emory University Hospital/Winship Cancer Institute - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2019-08-06 |
| Est. Completion | 2026-03-01 |
| Phase | Phase 2 |
What the registry record for NCT04022343 still lists
NCT04022343 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (91% lower).
The record links to 3 conditions, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Cabozantinib is the first listed.
NCT04022343 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT04022343 about?
NCT04022343 is a clinical study titled "Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer". This phase II clinical trial studies how well cabozantinib works in treating patients with kidney cancer before surgery. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT04022343?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2019-08-06. Estimated completion is 2026-03-01.
What conditions does trial NCT04022343 study?
This clinical trial studies the following conditions: Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8.
What interventions are being tested in trial NCT04022343?
The interventions under investigation include: Cabozantinib (DRUG).
Who is sponsoring clinical trial NCT04022343?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04022343 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04022343's enrollment target sits among peer trials
22 105th of 121 higher than 15 of 121 other Renal Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Renal Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)
RECRUITING · Phase 2
-
Contrast-Enhanced Ultrasound Imaging for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation
RECRUITING · Phase 2
-
Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations
RECRUITING · Phase 2
-
Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)
RECRUITING · Phase 2
-
Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
RECRUITING · Phase 2
-
A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI